{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Nieuwenhuyzen-de Boer GM"],"funding":["ZonMw"],"pagination":["4833-4843"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9246793"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["29(8)"],"pubmed_abstract":["<h4>Objective</h4>Standard surgical treatment of advanced-stage ovarian carcinoma with electrosurgery cannot always result in complete cytoreductive surgery (CRS), especially when many small metastases are found on the mesentery and intestinal surface. We investigated whether adjuvant use of a neutral argon plasma device can help increase the complete cytoreduction rate.<h4>Patients and methods</h4>327 patients with FIGO stage IIIB-IV epithelial ovarian cancer (EOC) who underwent primary or interval CRS were randomized to either surgery with neutral argon plasma (PlasmaJet) (intervention) or without PlasmaJet (control group). The primary outcome was the percentage of complete CRS. The secondary outcomes were duration of surgery, blood loss, number of bowel resections and colostomies, hospi"],"journal":["Annals of surgical oncology"],"pubmed_title":["Adjuvant Use of PlasmaJet Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Results of the PlaComOv-study, a Randomized Controlled Trial in The Netherlands."],"pmcid":["PMC9246793"],"funding_grant_id":["843001805"],"pubmed_authors":["Hofman LN","Boere IA","Ewing-Graham PC","Nieuwenhuyzen-de Boer GM","van Driel WJ","Werner HMJ","van Beekhuizen HJ","Haans L","Reesink-Peters N","Schoots IG","Nedelcu I","Dorman M","Hofhuis W","Willemsen S","van Haaften-de Jong AMLD","Beltman JJ","Piek JMJ","Baalbergen A"],"additional_accession":[]},"is_claimable":false,"name":"Adjuvant Use of PlasmaJet Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Results of the PlaComOv-study, a Randomized Controlled Trial in The Netherlands.","description":"<h4>Objective</h4>Standard surgical treatment of advanced-stage ovarian carcinoma with electrosurgery cannot always result in complete cytoreductive surgery (CRS), especially when many small metastases are found on the mesentery and intestinal surface. We investigated whether adjuvant use of a neutral argon plasma device can help increase the complete cytoreduction rate.<h4>Patients and methods</h4>327 patients with FIGO stage IIIB-IV epithelial ovarian cancer (EOC) who underwent primary or interval CRS were randomized to either surgery with neutral argon plasma (PlasmaJet) (intervention) or without PlasmaJet (control group). The primary outcome was the percentage of complete CRS. The secondary outcomes were duration of surgery, blood loss, number of bowel resections and colostomies, hospi","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-19T07:47:15.822Z","creation":"2022-07-08T08:11:25.556Z"},"accession":"S-EPMC9246793","cross_references":{"pubmed":["35552938"],"doi":["10.1245/s10434-022-11763-2"]}}